Verbatim response from Claude
I want to be straightforward with you on this:
What Happened
The FDA declared the GLP-1 shortage (semaglutide/tirzepatide) over, meaning compounding pharmacies largely lost legal authority to produce these at scale. Enforcement has been ongoing through 2024-2025.
Current Landscape (Be Cautious)
Some telehealth services were still navigating this, including:
- Hims & Hers - faced FDA scrutiny on their compounded offerings
- LifeMD/Ro - adjusted their offerings amid crackdowns
- Mochi Health - was operating in this space
- Henry - offered compounded options
However, I'd caution against me giving you a confident current list because:
- The situation is actively changing - services that offered compounded GLP-1s last month may have stopped
- Some providers are operating in legal gray areas
- Safety and quality of compounded versions vary significantly
- What I know may already be outdated
Better Steps
- Check each platform's current website directly
- Ask explicitly whether the medication is FDA-approved brand name or compounded
- Consult your doctor about branded options (Ozempic, Wegovy, Zepbound) and manufacturer savings programs
- Verify any compounding pharmacy is 503A or 503B accredited
Would you like help thinking through the branded medication access options instead?